NICE DMD Approval and EU Critical Medicines Progress

MarcusNICE sealed the givinostat deal for Duchenne muscular dystrophy this week. Third DMD treatment through their system, targeting around 530 people in England through the Innovative Medicines Fund.

SaraThe clinical evidence suggests five additional years of walking ability versus established care. But I'm looking at this commercial agreement - given the uncertainty beyond that timeframe, this had to be a significant risk-sharing arrangement.

MarcusAbsolutely. The IMF structure makes sense here - you're dealing with a progressive condition where the endpoint benefits are clear in the near term, but the long-term value story gets murky. Perfect use case for outcomes-based contracting.

SaraWhat's interesting is how this fits their broader rare disease strategy. They're clearly more willing to work within uncertainty when the unmet need is this stark. The commercial negotiation becomes the risk mitigation tool rather than demanding impossible evidence standards.

MarcusExactly. And it signals to other DMD assets in development that NICE will engage constructively if you bring realistic commercial terms that reflect the evidence limitations.

SaraThe EU moved forward with the Critical Medicines Act political agreement this week. EMA's positioning this as building on existing regulatory tools, but the real test is whether it actually strengthens supply chain resilience or just adds another layer of bureaucracy.

MarcusI'm skeptical about the practical impact. You've got EMA's Executive Steering Group on Shortages taking on supply chain vulnerability assessments, but vulnerability assessments don't manufacture APIs or solve geopolitical supply disruptions.

SaraThat's fair, but I think you're underestimating the coordination value. Right now, member states are operating in silos when shortages hit. If this creates genuine information sharing and early warning systems, it could prevent cascading shortages across borders.

MarcusBut that assumes member states will actually share commercially sensitive supply information in real time. The incentives aren't aligned - when shortages hit, it's every country for itself. I'd rather see investment in manufacturing capacity than more assessment frameworks.

SaraTrue, but the assessment piece could drive the investment decisions. If you can map vulnerabilities systematically, you can target where manufacturing redundancy is most critical. Without that intelligence, you're just throwing money at the problem.

MarcusThe HTACG capacity building programme is scaling up - seventeen national and regional HTA bodies from thirteen member states now participating. They're rolling out eLearning modules in multiple EU languages by end of May.

SaraThis is where the EU JCA implementation either succeeds or fails. You can have the most elegant joint assessment process on paper, but if the national assessors don't understand how to interpret and apply the outputs, it falls apart at country level.

MarcusThe language piece is crucial. Technical HTA assessment in your second language creates interpretation gaps that can shift reimbursement decisions. But I wonder about the practical uptake - are these assessors actually going through the modules, or is this just compliance theater?

SaraGood question. The real test comes when the first wave of JCA reports hit national systems. If assessors are struggling with the methodology or missing key nuances, you'll see it immediately in the national recommendation variations.

MarcusAnd that feeds back into manufacturer confidence in the process. If companies see wide variation in how JCA outputs get interpreted nationally, they'll start gaming the system - targeting friendly jurisdictions and avoiding the joint process where possible.

SaraISPOR 2026 is putting US drug pricing front and center. Monday's plenary covers Trump's most-favored-nation strategy and Medicare negotiations under the Inflation Reduction Act - analyzing economic, regulatory, and global implications.

MarcusAbout time. The IRA implementation has been running for over a year now, and we're finally getting real-world data on how price negotiations affect development decisions and global pricing strategies.

SaraThe global spillover effects are what I'm watching. Trump's MFN approach, if it actually gets implemented, fundamentally changes how companies think about international reference pricing. European HTA bodies need to understand these dynamics.

MarcusExactly. If US prices get anchored to international benchmarks more aggressively, it puts pressure on European payers to justify their own pricing decisions. The traditional free-riding relationship gets flipped.

SaraAnd it could accelerate value-based agreements in Europe. If companies can't rely on US revenues to subsidize lower European prices, they'll need more sophisticated risk-sharing to maintain access.

MarcusThese intersecting pressures - EU JCA standardization, US pricing reforms, supply chain vulnerabilities - they're reshaping the entire evidence and access landscape.

SaraThe companies adapting fastest to this new reality will have significant competitive advantages. The ones still operating with 2020 playbooks are going to struggle.

MarcusBack tomorrow. Show notes at outcomes-analytica.no.